Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Edgewise Therapeutics, Inc. (EWTX : NSDQ)

• Company Description    Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States. Number of Employees: 110

• Price / Volume Information    Yesterday's Closing Price: $13.87 Daily Weekly Monthly 20 Day Moving Average: 735,258 shares Shares Outstanding: 105.20 (millions) Market Capitalization: $1,459.13 (millions) Beta: 0.25 52 Week High: $38.12 52 Week Low: $10.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.05% -13.42% 12 Week 3.12% -13.26% Year To Date -48.05% -51.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1715 38TH ST - BOULDER,CO 80301 USA ph: 720-262-7002 fax: - ir@edgewisetx.com http://www.edgewisetx.com

• General Corporate Information    Officers Kevin Koch - President; Chief Executive Officer and Director Peter Thompson - Chairman and Director R. Michael Carruthers - Chief Financial Officer Alan Russell? - Chief Scientific Officer and Director Laura A. Brege - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28036F105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 105.20 Most Recent Split Date: (:1) Beta: 0.25 Market Capitalization: $1,459.13 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.45 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.38 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -30.30% vs. Previous Quarter: -2.38% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -30.95 12/31/24 - -26.85 ROA 06/30/25 - - 03/31/25 - -29.45 12/31/24 - -25.69 Current Ratio 06/30/25 - - 03/31/25 - 20.99 12/31/24 - 19.93 Quick Ratio 06/30/25 - - 03/31/25 - 20.99 12/31/24 - 19.93 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 4.10 12/31/24 - 4.84 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©